Value through Innovation16 January 2013
Boehringer Ingelheim Group of companies
In 2011, Boehringer Ingelheim's sales increased by 5 %.
Financial Highlights
| Boehringer Ingelheim group of companies |
2011 |
2010 |
Change |
|---|---|---|---|
| Net sales |
13,171 | 12,586 |
5 % |
| Net sales by region |
|||
| Europe |
31 % | 32 % |
|
| Americas |
46 % | 46 % |
|
| Asia, Australasia, Africa |
23 % | 22 % |
|
|
Net sales by business area |
|||
| Human Pharmaceuticals |
93 % | 93 % |
|
| Animal Health |
7 % | 7 % |
|
| Research and Development |
2,516 | 2,453 |
3 % |
| Personnel costs |
3,664 | 3,358 | 9 % |
| Average number of employees |
44,094 | 42,224 |
4 % |
| Operating income |
2,272 |
1,896
|
20 % |
| As % of net sales |
17, 3 % | 15.1% | |
| Income after taxes |
1,476 | 888 |
66 % |
| As % of net sales |
11,2 % | 7.1 % |
|
| Shareholders' equity |
7,466 |
6,474
|
15 % |
| Return on shareholders' equity |
22,8 % | 15.0 % |
|
| Cash Flow |
2,378 | 2,234 |
6 % |
| Investments in tangible assets |
458 | 519 |
-12 % |
| Depreciation of tangible assets |
535 | 498 |
7 % |
Amounts in millions of EUR, unless otherwise indicated
